Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 3/20 | 0.37 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14472340 | 1.00 | PRCP (0.44) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| SCHEMBL737577 | 0.98 | PRCP (0.46) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| SCHEMBL737244 | 0.98 | PRCP (0.46) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| SCHEMBL739240 | 0.98 | PRCP (0.46) | PRCPCYP19A1TSHRSMN1; SMN2AR | |
| Hydrochloric Acid SCHEMBL28764877 | 0.79 | HSD11B1 (0.34) | PRCPMEN1KMT2ALMNA | |
| SCHEMBL8266504 | 0.76 | PRCP (0.46) | PRCPCYP19A1TSHRARMEN1 | |
| SCHEMBL20915054 | 0.74 | PRCP (0.56) | PRCPCYP19A1TSHRMEN1KMT2A | |
| SCHEMBL4562 | 0.72 | SMN1; SMN2 (0.42) | CYP19A1TSHRSMN1; SMN2ARMEN1 | |
| SCHEMBL445133 | 0.72 | SMN1; SMN2 (0.42) | CYP19A1TSHRSMN1; SMN2ARMEN1 | |
| SCHEMBL16106147 | 0.72 | SMN1; SMN2 (0.42) | CYP19A1TSHRSMN1; SMN2ARMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891405-B2 | Furo[3,4-b]pyrrole-containing BTK inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-02-06 | — | — | US | disclosed |
| CN-116284057-A | Furano [3,4-b ] pyrrole-containing compounds | 正大天晴药业集团股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-112805287-B | BTK inhibitors containing furo [3,4-b ] pyrroles | 正大天晴药业集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20220033419-A1 | FURO[3,4-B]PYRROLE-CONTAINING BTK INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-02-03 | — | — | US | disclosed |
| EP-3851439-A1 | FURO[3,4-B]PYRROLE-CONTAINING BTK INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2021-06-10 | — | — | US | disclosed |
| CN-112805287-A | BTK inhibitors containing furo [3,4-b ] pyrroles | 正大天晴药业集团股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| WO-2020052628-A1 | FURO[3,4-B]PYRROLE-CONTAINING BTK INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-03-19 | — | — | WO | disclosed |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2019-10-24 | — | — | US | disclosed |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | HIRTH BRADFORD H | 2008-03-06 | — | — | US | disclosed |
| US-7265228-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-08-30 | — | — | US | disclosed |
| US-7196205-B2 | Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050222244-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-10-06 | — | — | US | disclosed |
| US-6855830-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050009872-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1409467-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | GENZYME CORPORATION | 2003-03-13 | — | — | US | disclosed |
| WO-2003008399-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222244-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | CYP19A1 3114/4885CA2 4610/4885PRCP 1736/4885 |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | CYP19A1 3114/4885CA2 4610/4885PRCP 1736/4885 |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | CYP19A1 3114/4885CA2 4610/4885PRCP 1736/4885 |
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | CYP19A1 3114/4885CA2 4610/4885PRCP 1736/4885 |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | CYP19A1 3114/4885CA2 4610/4885PRCP 1736/4885 |
| US-11891405-B2 | Furo[3,4-b]pyrrole-containing BTK inhibitor | BTK, SYK, LCK | CYP19A1 1972/4885CA2 2878/4885PRCP 2290/4885 |
| US-20050009872-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | CYP19A1 3114/4885CA2 4610/4885PRCP 1736/4885 |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | CYP19A1 3114/4885CA2 4610/4885PRCP 1736/4885 |
| US-20220033419-A1 | FURO[3,4-B]PYRROLE-CONTAINING BTK INHIBITOR | BTK, SYK, LCK | CYP19A1 1972/4885CA2 2878/4885PRCP 2290/4885 |
| US-20030050299-A1 | An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents | UGCG, UGGT1, LCLAT1 | CYP19A1 1621/4885CA2 2189/4885PRCP 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.